Autolus Therapeutics plc — Form 20-F transition report
Period clarification: Although the request identifies 2019 Q1, this filing reports the transition period from October 1 through December 31, 2018, following the company’s change to a December 31 fiscal year-end. It does not report the quarter ended March 31, 2019. The financial statements are prepared under U.S. GAAP; amounts below are U.S. dollars.
Business context and reporting period
Autolus is a clinical-stage biopharmaceutical company developing programmed T-cell cancer therapies. It has no products approved for sale and has not generated product revenue. The December 2018 transition-period financial statements were audited; the December 2017 comparative quarter was unaudited.
Key financial metrics
| Metric | Three months ended Dec. 31, 2018 | Comparable 2017 period |
|---|---|---|
| Grant income | $0.3 million | $0.2 million |
| Research and development expense | $17.7 million | $5.6 million |
| General and administrative expense | $7.6 million | $3.1 million |
| Net loss | $20.6 million | $7.5 million |
| Net loss per ordinary share, basic and diluted | $0.52 | Not stated in the comparative summary |
| Cash used in operating activities | $19.8 million | $8.8 million |
| Cash used in investing activities | $4.4 million | $0.8 million |
At December 31, 2018, cash was $217.5 million, current assets were $233.0 million, current liabilities were $21.1 million, and working capital was approximately $211.9 million. Total liabilities were $21.6 million. The filing reports no material financing commitments such as lines of credit or guarantees; it does not present a separate borrowing balance. Gross margin is not meaningful because there were no product sales.
Material changes versus the prior comparable period
- Net loss increased by $13.1 million, while operating expenses rose by $16.6 million. R&D expense increased $12.1 million, primarily reflecting clinical-program preparation and monitoring, higher headcount, and expanded facilities and research capabilities.
- G&A expense increased $4.5 million, driven by public-company, insurance, patent, commercial, investor-relations, facility, and personnel costs.
- Operating cash use increased by $11.0 million. Investing cash use rose with purchases of property and equipment, including investment in research and manufacturing capacity.
- Interest income rose to $0.7 million from $0.2 million, reflecting higher cash balances after the June 2018 IPO. Other income was $1.1 million, versus a $0.7 million expense, mainly due to foreign-exchange gains.
- Cash declined from $247.0 million at September 30, 2018 to $217.5 million at December 31, 2018. The three-month cash-flow statement reports a $5.3 million adverse exchange-rate effect on cash and restricted cash.
Outlook, risks, contingencies and unusual items
- Management expects significant operating losses and rising R&D and administrative costs as it advances clinical programs. It said cash on hand at December 31, 2018 was expected to fund current and planned operations into calendar 2021; the estimate depends on assumptions that may prove inaccurate.
- Additional financing may be needed. The company warns that inability to raise capital could delay, reduce, or terminate development programs; equity financing could dilute shareholders, while other financing or collaborations could require concessions of rights.
- Clinical success, patient enrollment, regulatory approvals, manufacturing scale-up, intellectual-property protection, competition, and future reimbursement are material uncertainties. No product candidate is assured of approval or commercialization.
- Operating lease obligations were $10.2 million at December 31, 2018. This schedule excluded several leases or arrangements then expected to commence or be finalized, including additional London and Enfield space and a later Rockville facility; their disclosed expected annual payments are material to future commitments.
- A $0.6 million UCL Business milestone liability was accrued as probable. The license also carries potential future regulatory, commercialization and sales milestones and royalties; amounts and timing are uncertain. No material litigation was reported.
- Unusual period items included a $0.4 million impairment of discontinued software, $3.4 million of share-based compensation, and significant foreign-currency effects. U.K. R&D tax credits contributed to a $2.6 million income-tax benefit; the company maintained a full valuation allowance against deferred tax assets.
Important facts for investors to verify
- Confirm the reporting period and distinguish this October–December 2018 transition report from a March 2019 quarter filing.
- Assess the cash-runway estimate against clinical-trial spending, capital investment, new lease commitments, and foreign-exchange exposure.
- Track clinical enrollment, safety and efficacy updates, regulatory milestones, and manufacturing readiness for the company’s candidates.
- Review eligibility and timing of U.K. R&D tax-credit receipts, along with the assumptions supporting the deferred-tax valuation allowance.
- Monitor potential UCLB milestone and royalty obligations, share-based compensation, and any future financing or dilution.